719 related articles for article (PubMed ID: 17905417)
21. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
22. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM
Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540
[TBL] [Abstract][Full Text] [Related]
23. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
[TBL] [Abstract][Full Text] [Related]
25. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
26. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
27. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
28. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
30. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
[TBL] [Abstract][Full Text] [Related]
32. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
Hauser H; Shen L; Gu QL; Krueger S; Chen SY
Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
[TBL] [Abstract][Full Text] [Related]
33. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
Li Y; Subjeck J; Yang G; Repasky E; Wang XY
Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response.
Tan J; Yang NS; Turner JG; Niu GL; Maassab HF; Sun J; Herlocher ML; Chang AE; Yu H
Cancer Gene Ther; 1999; 6(4):331-9. PubMed ID: 10419051
[TBL] [Abstract][Full Text] [Related]
35. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
[TBL] [Abstract][Full Text] [Related]
36. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
37. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells.
Smahel M; Síma P; Ludvíková V; Vonka V
Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen.
Hsu KF; Hung CF; Cheng WF; He L; Slater LA; Ling M; Wu TC
Gene Ther; 2001 Mar; 8(5):376-83. PubMed ID: 11313814
[TBL] [Abstract][Full Text] [Related]
39. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
